Literature DB >> 31185710

KASL clinical practice guidelines for management of chronic hepatitis B.

.   

Abstract

Entities:  

Keywords:  Chronic hepatitis B; KASL guidelines; Treatment

Mesh：

Substances：

Year:  2019        PMID： 31185710      PMCID： PMC6589848          DOI： 10.3350/cmh.2019.1002

Source DB:  PubMed          Journal:  Clin Mol Hepatol        ISSN： 2287-2728


× No keyword cloud information.
  574 in total

1.  Meta-analysis: antiviral treatment for hepatitis D.

Authors:  C Triantos; M Kalafateli; V Nikolopoulou; A Burroughs
Journal:  Aliment Pharmacol Ther       Date:  2012-01-24       Impact factor: 8.171

Review 2.  Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy.

Authors:  Winnie Yeo; Philip J Johnson
Journal:  Hepatology       Date:  2006-02       Impact factor: 17.425

Review 3.  Influence of anti-HBc positive organ donor in lung donor selection.

Authors:  Carlos Chamorro; Manuel Aparicio
Journal:  Arch Bronconeumol       Date:  2012-06-17       Impact factor: 4.872

4.  Hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy in patients with diffuse large B cell lymphoma.

Authors:  Wei Ping Liu; Xiao Pei Wang; Wen Zheng; Ling Yan Ping; Chen Zhang; Gui Qiang Wang; Yu Qin Song; Jun Zhu
Journal:  Leuk Lymphoma       Date:  2016-01-04

5.  Serum HBV core-related antigen is a good predictor for spontaneous HBeAg seroconversion in chronic hepatitis B patients.

Authors:  Guangjun Song; Ruifeng Yang; Huiying Rao; Bo Feng; Hui Ma; Qian Jin; Lai Wei
Journal:  J Med Virol       Date:  2016-08-31       Impact factor: 2.327

6.  Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin.

Authors:  J S Markowitz; P Martin; A J Conrad; J F Markmann; P Seu; H Yersiz; J A Goss; P Schmidt; A Pakrasi; L Artinian; N G Murray; D K Imagawa; C Holt; L I Goldstein; R Stribling; R W Busuttil
Journal:  Hepatology       Date:  1998-08       Impact factor: 17.425

7.  The natural history of asymptomatic hepatitis B surface antigen carriers.

Authors:  R de Franchis; G Meucci; M Vecchi; M Tatarella; M Colombo; E Del Ninno; M G Rumi; M F Donato; G Ronchi
Journal:  Ann Intern Med       Date:  1993-02-01       Impact factor: 25.391

8.  Serologic and DNA follow-up data from HBsAg-positive patients treated with orthotopic liver transplantation.

Authors:  R B Freeman; H Sanchez; W D Lewis; B Sherburne; W H Dzik; U Khettry; S Hing; J B Zeldis; R L Jenkins
Journal:  Transplantation       Date:  1991-04       Impact factor: 4.939

9.  Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.

Authors:  S K Sarin; M Kumar; G K Lau; Z Abbas; H L Y Chan; C J Chen; D S Chen; H L Chen; P J Chen; R N Chien; A K Dokmeci; Ed Gane; J L Hou; W Jafri; J Jia; J H Kim; C L Lai; H C Lee; S G Lim; C J Liu; S Locarnini; M Al Mahtab; R Mohamed; M Omata; J Park; T Piratvisuth; B C Sharma; J Sollano; F S Wang; L Wei; M F Yuen; S S Zheng; J H Kao
Journal:  Hepatol Int       Date:  2015-11-13       Impact factor: 6.047

10.  Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis B.

Authors:  Robert Perrillo; Maria Buti; Francois Durand; Michael Charlton; Adrian Gadano; Guido Cantisani; Che-Chuan Loong; Kimberly Brown; Wenhua Hu; Juan Carlos Lopez-Talavera; Cyril Llamoso
Journal:  Liver Transpl       Date:  2013-08       Impact factor: 5.799
View more
  36 in total

Review 1.  Withdrawal of Nucleos(t)ide Analogues in Hepatitis B e Antigen-Negative Patients: An Asian Perspective.

Authors:  Tung-Hung Su; Jia-Horng Kao
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-01-13

2.  Switching from Tenofovir-Based Combination Therapy to Tenofovir Monotherapy in Multidrug-Experienced Chronic Hepatitis B Patients: a 5-Year Experience at Two Centers.

Authors:  Jung Hun Kim; Jeong Han Kim; Won Hyeok Choe; So Young Kwon; Byung-Chul Yoo; Eileen L Yoon; Seong Hee Kang
Journal:  Antimicrob Agents Chemother       Date:  2022-07-13       Impact factor: 5.938

3.  Study on the Retreatment, Outcome, and Potential Predictors of Recurrence in Patients With Recurrence of Hepatitis B After Functional Cure.

Authors:  Xiao Lin; Aixin Song; Junfeng Lu; Sujun Zheng; Zhongjie Hu; Lina Ma; Zhenhuan Cao; Hong Li; Yanhong Zheng; Shan Ren; Xinyue Chen
Journal:  Front Immunol       Date:  2022-07-04       Impact factor: 8.786

Review 4.  Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases.

Authors:  Han Ah Lee; Young Chang; Pil Soo Sung; Eileen L Yoon; Hye Won Lee; Jeong-Ju Yoo; Young-Sun Lee; Jihyun An; Do Seon Song; Young Youn Cho; Seung Up Kim; Yoon Jun Kim
Journal:  Clin Mol Hepatol       Date:  2022-07-01

Review 5.  The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection.

Authors:  Jung Hwan Yu; Soon Gu Cho; Young-Joo Jin; Jin-Woo Lee
Journal:  Clin Mol Hepatol       Date:  2021-11-26

6.  Increasing on-treatment hepatocellular carcinoma risk with decreasing baseline viral load in HBeAg-positive chronic hepatitis B.

Authors:  Won-Mook Choi; Gi-Ae Kim; Jonggi Choi; Seungbong Han; Young-Suk Lim
Journal:  J Clin Invest       Date:  2022-05-16       Impact factor: 19.456

7.  Risk of Hepatitis B Virus (HBV) Reactivation in Patients with Immune-Mediated Inflammatory Diseases Receiving Biologics: Focus on the Timing of Biologics after Anti-HBV Treatment.

Authors:  Soo Min Ahn; Jonggi Choi; Byong Duk Ye; Suk-Kyun Yang; Ji Seon Oh; Yong-Gil Kim; Chang-Keun Lee; Bin Yoo; Sang Hyoung Park; Seokchan Hong
Journal:  Gut Liver       Date:  2021-11-29       Impact factor: 4.321

8.  Moving Fast Toward Hepatitis B Virus Elimination.

Authors:  Leda Bassit; Suzane Kioko Ono; Raymond F Schinazi
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

9.  The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B.

Authors:  Hye Won Lee; Hyun Woong Lee; Jae Seung Lee; Yun Ho Roh; Hyein Lee; Seung Up Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Beom Kyung Kim
Journal:  J Hepatocell Carcinoma       Date:  2021-05-25

10.  The FIB-4 Index Is a Useful Predictor for the Development of Hepatocellular Carcinoma in Patients with Coexisting Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B.

Authors:  Minah Kim; Yeonju Lee; Jun Sik Yoon; Minjong Lee; So Shin Kye; Sun Woong Kim; Yuri Cho
Journal:  Cancers (Basel)       Date:  2021-05-11       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.